CYMS101 for multiple sclerosis
phase 1drug program · high · Fri Oct 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat refractory relapsing-remitting multiple sclerosis through immune modulation by tolerogenic fibroblasts.
Intravenous administration of 100 million tolerogenic fibroblasts in a feasibility study assessing primary safety and secondary efficacy endpoints in 5 patients with relapsing-remitting MS resistant to interferon.
Clinical study record exists for tolerogenic fibroblasts in refractory MS; company update said it was preparing to submit an IND for CYMS101 in multiple sclerosis.
The clinical trial rationale states fibroblasts demonstrated immune modulatory and therapeutic activity in the EAE model of multiple sclerosis and other autoimmune/inflammatory disease models; clinical efficacy was not yet established in the supplied material.
CYPS317 for psoriasis
preclinicaldrug program · high · Fri Oct 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat psoriasis and potentially other inflammatory diseases using fibroblast spheroids with immunomodulatory activity.
Human dermal fibroblast-derived 3D spheroids tested in an imiquimod-induced psoriasis mouse model; company described CYPS317 as a fibroblast spheroid product candidate for psoriasis.
Company update said it was preparing to submit an IND for psoriasis with CYPS317.
In the supplied bioRxiv abstract, HDF spheroids reduced mild psoriasis severity by 35% after a single dose and moderate-to-severe psoriasis by 36% after repeated doses, with no acute or chronic toxicity observed.
CYTER915 cancer program
preclinicaldrug program · low · Fri Oct 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop fibroblast-based therapeutic options for cancer, including hematopoietic cancers, based on the supplied company update and pipeline listing.
Fibroblast-based therapeutic approach; detailed intervention protocol was not provided in the supplied material.
Company update referenced options for hematopoietic cancers and age-related immune decline; CYTER915 is listed in the company pipeline.
Injectable thymus micro-organoid program
preclinicalresearch program · high · Fri Sep 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Address thymic decline or insufficiency by generating functional T cells through transplantable, scalable thymic micro-organoids.
Cryopreservable injectable thymic micro-organoids generated from selectively screened fibroblasts and murine thymic cells, administered subcutaneously in mouse studies.
2025 bioRxiv preclinical study describing rapid and scalable subcutaneously administered murine thymus micro-organoids.
Organoids expressed genes needed for T cell development, generated functional beta, gamma-delta, NKT, and FoxP3+ regulatory T cells in T cell-deficient mice, produced diverse TCR repertoires, responded to stimulation, and delayed B16 melanoma growth when derived from pmel-1 thymocytes.
Thymic micro-organoid program
preclinicalresearch program · medium · Fri Sep 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Address thymic decline or thymic insufficiency by generating functional T cells from transplantable thymic micro-organoids.
Subcutaneously administered, cryopreservable, injectable micro-organoids generated from selectively screened fibroblasts and murine thymic cells.
2025 bioRxiv publication describing a rapid and scalable murine thymus micro-organoid system.
The supplied abstract reports that injected organoids gave rise to functional T cells in vitro and in vivo, produced diverse TCR repertoires, responded to stimulation, and delayed B16 melanoma growth in a pmel-1 thymocyte-derived model.
CYWC628 for diabetic foot ulcers
phase 1drug program · high · Mon Sep 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat refractory diabetic foot ulcers and evaluate safety, tolerability, and efficacy compared with standard of care.
Human dermal fibroblast spheroids administered for up to 12 weeks as low- or high-dose CYWC628 plus standard of care in a prospective, multicentre, randomized clinical trial.
ClinicalTrials.gov record for a randomized trial evaluating CYWC628 in refractory diabetic foot ulcers; company update said it was advancing manufacturing preparations for the Phase 1/2 DFU trial.
CYWC628 for refractory diabetic foot ulcers
phase 2drug program · high · Mon Sep 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate safety, tolerability, and efficacy of human dermal fibroblast spheroids for refractory diabetic foot ulcers compared with standard of care.
Prospective multicentre randomized clinical trial of standard of care plus low- or high-dose CYWC628 for up to 12 weeks versus standard of care only.
ClinicalTrials.gov record for a controlled trial in refractory diabetic foot ulcers.
Human dermal fibroblast spheroids for psoriasis
preclinicaldrug program · medium · Mon Aug 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop fibroblast spheroid therapy as an immunomodulatory treatment for psoriasis and potentially other inflammatory diseases.
Human dermal fibroblasts organized into three-dimensional spheroids and tested by intravenous administration in an imiquimod-induced psoriasis mouse model.
2025 bioRxiv preclinical study of HDF spheroids in a psoriasis mouse model.
HDF spheroids reduced mild psoriasis severity by 35% after a single dose and moderate-to-severe psoriasis by 36% after repeated doses; they normalized blood cell counts, reduced spleen enlargement, improved cytokine dysregulation, reduced epidermal thickening and immune infiltration, inhibited monocyte production and infiltration, and showed no acute or chronic toxicity in the supplied abstract.
Tolerogenic fibroblasts for refractory multiple sclerosis
phase 1drug program · medium · Mon Sep 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Assess safety and preliminary efficacy of tolerogenic fibroblasts in relapsing-remitting multiple sclerosis resistant to interferon.
Feasibility study administering 100 million tolerogenic fibroblasts intravenously to 5 patients, with neurologic, quality-of-life, and gadolinium-enhanced MRI assessments.
ClinicalTrials.gov feasibility study record for refractory multiple sclerosis.
Anti-aging splenic involution reversal program
exploratoryresearch program · low
Develop anti-aging applications aimed at splenic involution reversal.
Fibroblast-platform program; the supplied material does not provide specific intervention details for the public codename.
Listed in the company pipeline and company description identifies splenic involution reversal as an anti-aging application.
Anti-aging thymic involution reversal program
exploratoryresearch program · low
Develop anti-aging applications aimed at thymic involution reversal.
Fibroblast-platform program; the supplied material does not provide specific intervention details for the public codename.
Listed in the company pipeline and company description identifies thymic involution reversal as an anti-aging application.
Cancer fibroblast program
undiscloseddrug program · low
Develop a fibroblast-platform program for cancer applications.
Fibroblast cell-based or fibroblast-derived treatment approach; specific intervention details were not supplied.
Listed in the company pipeline and company description identifies cancer as one of the platform's program areas.
CYAPO913 anti-aging program
undiscloseddrug program · low
Develop fibroblast-derived or fibroblast-based treatments for anti-aging applications, including reversal of thymic and splenic involution as described in the supplied company analysis.
Fibroblast platform program; detailed protocol was not provided in the supplied material.
Listed in the company pipeline among fibroblast platform programs.
CybroCell for degenerative disc disease
undiscloseddrug program · medium
Develop a fibroblast-based therapy for degenerative disc disease.
Fibroblast cell-based regenerative medicine program; supplied materials list degenerative disc disease as a FibroBiologics program area and include spine-related publications.
Listed on the company pipeline page and supported by spine publications referenced on the company publications page.
Fibroblast platform
undisclosedplatform · high
Support development of fibroblast cell-based therapies and fibroblast-derived treatments for chronic diseases across degenerative disc disease, multiple sclerosis, wound healing, cancer, psoriasis, and anti-aging applications.
Proprietary fibroblast platform for cell-based therapies, fibroblast-derived spheroids, immune modulation, and regenerative medicine applications.
Company described itself as holding more than 150 issued or pending patents in the supplied site analysis; later public-record excerpts describe 270+ patents issued and pending.
FibroMune and PneumoBlast COVID-19 program
undisclosedresearch program · low
Investigate a multi-pronged fibroblast-related approach for COVID-19.
Publication-listed program titled “Multi-Pronged Attack on COVID-19: FibroMune™ and PneumoBlast”; detailed method was not provided in the supplied material.
Listed on the company publications page in the supplied site analysis.
